Improving patient access to life-enhancing medications
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

We offer patients better, safer & more accessible medicines.
For investors
More for investorsNews & Events


Wilsons investor conference presentation
26 May 2022
Mayne Pharma Group Limited presentation at Wilsons Rapid Insights conference on 26 May 2022.
Learn more


Mayne Pharma recipient of $4.8m Federal Government Grant
9 May 2022
Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.
Learn more


Non Executive Director appointment
22 Mar 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.
Learn more


Mayne Pharma 2022 Half Year Results Media Release
25 Feb 2022
Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.
Learn more


Mayne Pharma expands US dermatology portfolio
10 Feb 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.
Learn more


Non Executive Director appointment and retirement
17 Jan 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.
Learn more